{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:06:59Z","timestamp":1753891619479,"version":"3.41.2"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Although renal dysfunction is associated with adverse clinical outcomes in patients with atrial fibrillation (AF) following stroke, the impact of renal function variability is unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>This study aimed to assess the association between renal function variability and various adverse clinical outcomes in patients with transient ischemic attack (TIA)\/ischemic stroke and atrial fibrillation (AF).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a population-based study and retrospectively identified patients hospitalized with a diagnosis of TIA\/ischemic stroke and AF during 2016\u20132020 using the Clinical Data Analysis and Reporting System of Hong Kong. Serial serum creatinine tested upon the onset of TIA\/ischemic stroke and during their subsequent follow-up was collected. Renal function variability was calculated using the coefficient of variation of the estimated glomerular filtration rate (eGFR). Clinical endpoints that occurred during the study period were captured and included ischemic stroke\/systemic embolism, intracerebral hemorrhage (ICH), total bleeding, major adverse cardiovascular events (MACE), cardiovascular, non-cardiovascular, and all-cause mortality. Competing risk regression and Cox proportional hazard regression models were used to assess the associations of renal function variability with the outcomes of interest.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 3,809 patients (mean age 80\u2009\u00b1\u200910\u2009years, 43% men) who satisfied the inclusion and exclusion criteria were followed up for a mean of 2.5\u2009\u00b1\u20091.5\u2009years (9,523 patient-years). The mean eGFR was 66\u2009\u00b1\u200922\u2009mL\/min\/1.73\u2009m<jats:sup>2<\/jats:sup> at baseline, and the median number of renal function tests per patient during the follow-up period was 20 (interquartile range 11\u201335). After accounting for potential confounders, a greater eGFR variability was associated with increased risks of recurrent ischemic stroke\/systemic embolism [fully adjusted subdistribution hazard ratio 1.11, 95% confidence interval (CI) 1.03\u20131.20], ICH (1.17, 1.01\u20131.36), total bleeding (1.13, 1.06\u20131.21), MACE (1.22, 1.15\u20131.30), cardiovascular (1.49, 1.32\u20131.69), non-cardiovascular (1.43, 1.35\u20131.52), and all-cause mortality (fully adjusted hazard ratio 1.44, 1.39\u20131.50).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Visit-to-visit renal function variability is independently associated with adverse clinical outcomes in TIA\/ischemic stroke patients with AF. Further large-scale studies are needed to validate our results.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2024.1294022","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T13:04:16Z","timestamp":1713791056000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of renal function variability on long-term prognosis in ischemic stroke patients with atrial fibrillation"],"prefix":"10.3389","volume":"15","author":[{"given":"Xiao","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-fung","family":"Sin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kay-Cheong","family":"Teo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William C. Y.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuen-Kwun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxanna K. C.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua W.","family":"Fok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonaventure Y.","family":"Ip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hon Hang","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsz Ching","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bun","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwin Kin-Keung","family":"Yip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Desmond Y. H.","family":"Yap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kui-Kai","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","article-title":"2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the Management of Patients with Atrial Fibrillation a Report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society","volume":"74","author":"January","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"euab065","DOI":"10.1093\/europace\/euab065","article-title":"2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist Oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.2165\/00003088-200544120-00003","article-title":"Comparative pharmacokinetics of vitamin K antagonists","volume":"44","author":"Ufer","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1161\/STROKEAHA.114.006881","article-title":"Risk of thromboembolic events in atrial fibrillation with chronic kidney disease","volume":"46","author":"Zeng","year":"2018","journal-title":"Stroke"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1161\/CIRCULATIONAHA.108.816082","article-title":"Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation","volume":"119","author":"Go","year":"2009","journal-title":"Circulation"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ahj.2017.12.017","article-title":"Changes in glomerular filtration rate and outcomes in patients with atrial fibrillation","volume":"198","author":"Fauchier","year":"2018","journal-title":"Am Heart J"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/ki.2012.276","article-title":"Greater variability in kidney function is associated with an increased risk of death","volume":"82","author":"al-Aly","year":"2012","journal-title":"Kidney Int"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1053\/j.ajkd.2020.10.016","article-title":"Estimated GFR variability and risk of cardiovascular events and mortality in SPRINT (systolic blood pressure intervention trial)","volume":"78","author":"Malhotra","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/nep.14037","article-title":"Association between higher variability in kidney function and long-term mortality","volume":"27","author":"Ryu","year":"2022","journal-title":"Nephrology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1001\/jamacardio.2020.5592","article-title":"Association of Visit-to-Visit Variability in kidney function and serum electrolyte indexes with risk of adverse clinical outcomes among patients with heart failure with preserved ejection fraction","volume":"6","author":"Segar","year":"2021","journal-title":"JAMA Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"18055","DOI":"10.1038\/s41598-019-54528-w","article-title":"Fluctuating renal function and the risk of incident atrial fibrillation: a nationwide population-based study","volume":"9","author":"Kwon","year":"2019","journal-title":"Sci Rep"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/jth.13985","article-title":"Variation of renal function over time is associated with major bleeding in patients treated with direct oral anticoagulants for atrial fibrillation","volume":"16","author":"Becattini","year":"2018","journal-title":"J Thromb Haemost"},{"year":"2022","key":"ref17"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1053\/j.gastro.2015.05.002","article-title":"Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: a population-based study","volume":"149","author":"Chan","year":"2015","journal-title":"Gastroenterology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"h6926","DOI":"10.1136\/bmj.h6926","article-title":"Cardiovascular outcomes associated with use of clarithromycin: population based study","volume":"352","author":"Wong","year":"2016","journal-title":"BMJ"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.hrthm.2016.03.049","article-title":"Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: a population-wide cohort study","volume":"13","author":"Chan","year":"2016","journal-title":"Heart Rhythm"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1053\/j.ajkd.2011.02.393","article-title":"GFR estimating equations in a multiethnic Asian population","volume":"58","author":"Teo","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"","journal-title":"J Am Stat Assoc"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1161\/STROKEAHA.115.009076","article-title":"Day-by-day blood pressure variability and functional outcome after acute ischemic stroke","volume":"46","author":"Fukuda","year":"2015","journal-title":"Stroke"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/01.hjh.0000160205.81652.5a","article-title":"A reliable index for the prognostic significance of blood pressure variability","volume":"23","author":"Mena","year":"2005","journal-title":"J Hypertens"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"10165","DOI":"10.1038\/s41598-021-89442-7","article-title":"Distribution of estimated glomerular filtration rate and determinants of its age dependent loss in a German population-based study","volume":"11","author":"Waas","year":"2021","journal-title":"Sci Rep"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/MNH.0000000000000634","article-title":"Direct oral anticoagulants in chronic kidney disease: an update","volume":"29","author":"Mavrakanas","year":"2020","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0140-6736(10)60308-X","article-title":"Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension","volume":"375","author":"Rothwell","year":"2010","journal-title":"Lancet"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/jhh.2013.19","article-title":"Relationships between metrics of visit-to-visit variability of blood pressure","volume":"27","author":"Levitan","year":"2013","journal-title":"J Hum Hypertens"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1002\/ana.25489","article-title":"Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation","volume":"85","author":"Seiffge","year":"2019","journal-title":"Ann Neurol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e180171","DOI":"10.1001\/jamanetworkopen.2018.0171","article-title":"Prestroke and poststroke antithrombotic therapy in patients with atrial fibrillation: results from a Nationwide cohort","volume":"1","author":"Gundlund","year":"2018","journal-title":"JAMA Netw Open"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"888660","DOI":"10.3389\/fphar.2022.888660","article-title":"Plasma rivaroxaban level in patients with early stages of chronic kidney disease\u2014relationships with renal function and clinical events","volume":"13","author":"Sin","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1111\/jth.14457","article-title":"Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants","volume":"17","author":"Testa","year":"2019","journal-title":"J Thromb Haemost"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/jth.14001","article-title":"Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants","volume":"16","author":"Testa","year":"2018","journal-title":"J Thromb Haemost"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12959-021-00351-1","article-title":"The impact on renal function after long-term use of anticoagulants in atrial fibrillation patients","volume":"19","author":"Lee","year":"2021","journal-title":"Thromb J"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1111\/bcp.14350","article-title":"Association of different oral anticoagulants use with renal function worsening in patients with atrial fibrillation: a multicentre cohort study","volume":"86","author":"Pastori","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1053\/j.ajkd.2022.07.017","article-title":"Cardiorenal outcomes among patients with atrial fibrillation treated with Oral anticoagulants","volume":"81","author":"Trevisan","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ijcard.2022.01.063","article-title":"Renal decline in patients with non-valvular atrial fibrillation treated with rivaroxaban or warfarin: a population-based study from the United Kingdom","volume":"352","author":"P\u00e9rez","year":"2022","journal-title":"Int J Cardiol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1161\/CIRCULATIONAHA.122.062752","article-title":"Direct Oral anticoagulants versus warfarin across the Spectrum of kidney function: patient-level network meta-analyses from COMBINE AF","volume":"147","author":"Harrington","year":"2023","journal-title":"Circulation"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1055\/a-1450-8178","article-title":"2021 update of the International Council for Standardization in haematology recommendations for laboratory measurement of direct Oral anticoagulants","volume":"121","author":"Douxfils","year":"2021","journal-title":"Thromb Haemost"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1111\/jgs.14288","article-title":"Potential effect of substituting estimated glomerular filtration rate for estimated creatinine clearance for dosing of direct Oral anticoagulants","volume":"64","author":"Schwartz","year":"2016","journal-title":"J Am Geriatr Soc"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1161\/STROKEAHA.119.026054","article-title":"Non\u2013vitamin K antagonist Oral anticoagulants versus warfarin in Asians with atrial fibrillation","volume":"50","author":"Xue","year":"2019","journal-title":"Stroke"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ijcard.2014.11.182","article-title":"Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: time for a reappraisal","volume":"180","author":"Lip","year":"2015","journal-title":"Int J Cardiol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.chest.2019.04.108","article-title":"Effectiveness and safety of four direct Oral anticoagulants in Asian patients with nonvalvular atrial fibrillation","volume":"156","author":"Chan","year":"2019","journal-title":"Chest"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1294022\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T13:04:20Z","timestamp":1713791060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1294022\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,22]]},"references-count":44,"alternative-id":["10.3389\/fneur.2024.1294022"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1294022","relation":{},"ISSN":["1664-2295"],"issn-type":[{"type":"electronic","value":"1664-2295"}],"subject":[],"published":{"date-parts":[[2024,4,22]]},"article-number":"1294022"}}